Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.
Robert J. Kreitman(National Cancer Institute), Ira Pastan(National Cancer Institute), Liqiang Xi(Center for Cancer Research), Seth M. Steinberg(National Institutes of Health), Katherine R. Calvo(National Institutes of Health Clinical Center), Lacey James-Echenique(MRC Laboratory of Molecular Biology), Constance M. Yuan(National Cancer Institute), Raul C. Braylan(Center for Cancer Research), Evgeny Arons(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Hong Zhou(National Institutes of Health), Irina Marić(Center for Cancer Research), Julie Feurtado(National Institutes of Health), Mark Raffeld(National Cancer Institute)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744